07.05.2012

Roche Gives Up on Heart Drug after Trial Disappoints

Swiss drugmaker Roche has ended efforts to develop a heart disease drug which some industry analysts had estimated could have achieved $10 billion in annual sales, after poor results from a late-stage trial. more12.03.2012

Bayer Sounds Out Debt Market with Eye On Deals

Bayer is sounding out its debt financing options with banks to prepare for takeover opportunities such as one that may arise from Pfizer's mooted exit from veterinary medicine, people familiar with the matter said. Germany's largest drugmaker is encouraged by increasingly favorable market conditions for corporate bond issuers but is not eyeing a specific takeover deal, the sources said. more10.10.2011

Kenneth Frazier To Succeed Richard Clark as Merck & Co. Chair

Merck and Co. announced the retirement of its Chairman Richard Clark, effective Dec. 1. Kenneth Frazier, president of chief executive officer will succeed as chairman. more23.08.2011

Richard DeLuca Named President, Merck Animal Health

Merck & Co. said it appointed Richard DeLuca Jr. as executive vice president and president, Merck Animal Health, effective Sept. 15. DeLuca will report to Kenneth Frazier, Merck's president and chief executive, and would serve on the company's executive committee. more01.08.2011

Merck Q2 Profit Soars; 13% Job Reductions Planned by 2015

Merck & Co said its second-quarter net income attributable to the company jumped to $2.02 billion or $0.65 per share from $752 million or $0.24 per share last year. more21.07.2011

Merck Inks New Non-Exclusive Agreement With Roche

Merck & Co said it has signed a new non-exclusive agreement with Roche, through the companies' respective subsidiaries, for the global promotion, upon appropriate marketing approvals, of Victrelis as part of a triple combination therapy regimen with peginterferon alfa and ribavirin. more21.06.2011

Merck Loses Bid To Recoup $473 Million In U.S.

A federal appeals court rejected Merck & Co's bid for a new trial to obtain $472.9 million of federal income tax refunds that the drugmaker believes it deserves. The 3rd U.S. Circuit Court of Appeals unanimously upheld a 2008 ruling by U.S. District Judge Katharine Hayden in Newark, New Jersey against Schering-Plough Corp, which Merck bought the following year for roughly $45.9 billion. more14.06.2011

The World Of Biosimilars

Doubled-Edged Sword - The emergence of biosimilars has caused very large ripples in the biopharma pond, and has recently been called the most "disruptive technology" of the decade. True to a point, but dynamic change for some is usually accompanied by significant opportunity for others. This is the "double-edged sword" paradox of the biosimilars market.

In simple terms, biosimilars are the biotech industry's version of chemical generics. more08.06.2011

Roche to Provide Tests for Merck Cancer Drugs

Switzerland's Roche Holding will help develop diagnostic tests for Merck & Co's portfolio of experimental cancer medicines under a collaboration announced by the two drugmakers on Tuesday. more02.05.2011

Merck Reports Higher-Than-Expected Earnings

Merck & Co reported higher-than-expected first-quarter earnings, fueled by strong sales of its drugs for diabetes, asthma and rheumatoid arthritis. more